{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:38:35Z","timestamp":1780090715700,"version":"3.54.0"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:p>Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by the destruction of pancreatic \u03b2-cells, necessitating lifelong exogenous insulin. This review synthesizes key advances that are shifting T1DM management from symptomatic control to disease modification and potential cure. We examine progress in novel insulin formulations and automated insulin delivery systems, alongside groundbreaking immunomodulatory therapies and gene-edited stem cell therapies that aim to restore native \u03b2-cell function and achieve insulin independence. The article also discusses the potential of phytomedicines and gut microbiota modulation. This review provides insights into the unique challenges of implementing these innovations within the Chinese healthcare context, highlighting the need for high-quality clinical research, personalized strategies, and improved healthcare accessibility to enhance long-term patient outcomes.<\/jats:p>","DOI":"10.3389\/fcdhc.2025.1651061","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:29:08Z","timestamp":1760074148000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances and future perspectives in the treatment and prognosis of type 1 diabetes mellitus"],"prefix":"10.3389","volume":"6","author":[{"given":"Yuqing","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"Sanra-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a who consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70012","article-title":"National burden and risk factors of diabetes mellitus in China from 1990 to 2021: results from the global burden of disease study 2021","volume":"16","author":"Deng","year":"2024","journal-title":"J. Diabetes"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078432","article-title":"Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study","volume":"385","author":"Yang","year":"2024","journal-title":"Bmj"},{"key":"B5","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc21-1752","article-title":"The incidence of adult-onset type 1 diabetes: a systematic review from 32 countries and regions","volume":"45","author":"Harding","year":"2022","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05571-8","article-title":"Type 1 diabetes in 2017: global estimates of incident and prevalent cases in children and adults","volume":"64","author":"Green","year":"2021","journal-title":"Diabetologia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5295","article-title":"Incidence of type 1 diabetes in China, 2010-13: population based study","volume":"360","author":"Weng","year":"2018","journal-title":"Bmj"},{"key":"B8","unstructured":"IDF diabetes atlas\n          \n          2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.2103","article-title":"Prevalence of type 1 diabetes among us children and adults by age, sex, race, and ethnicity","volume":"331","author":"Fang","year":"2024","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc24-SREV","article-title":"Summary of revisions: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":". Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00853-0","article-title":"Heterogeneity and endotypes in type 1 diabetes mellitus","volume":"19","author":"Redondo","year":"2023","journal-title":"Nat. Rev. Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2025.05.006","article-title":"Development of insulin and its pharmacology and perioperative use: a narrative review","volume":"135","author":"Dhatariya","year":"2025","journal-title":"Br. J. Anaesth"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (begin basal-bolus type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Heller","year":"2012","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015597915","article-title":"New insulin glargine 300 u\/ml for the treatment of type 1 and type 2 diabetes mellitus","volume":"49","author":"Goldman","year":"2015","journal-title":"Ann. Pharmacother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12052","article-title":"Insulin degludec: overview of a novel ultra long-acting basal insulin","volume":"15","author":"Gough","year":"2013","journal-title":"Diabetes Obes. Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13616","article-title":"A comparative effectiveness study of degludec and insulin glargine 300 u\/ml in insulin-naive patients with type 2 diabetes","volume":"21","author":"Tibaldi","year":"2019","journal-title":"Diabetes Obes. Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0464-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of insulin glargine 300 u\/ml","volume":"56","author":"Clements","year":"2017","journal-title":"Clin. Pharmacokinet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00257","article-title":"Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J. Med. Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02179-7","article-title":"Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (onwards 6): a phase 3a, randomised, open-label, treat-to-target trial","volume":"402","author":"Russell-Jones","year":"2023","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2395","article-title":"Novel once-weekly basal insulin fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes","volume":"46","author":"Kazda","year":"2023","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-2396","article-title":"Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial","volume":"46","author":"Bue-Valleskey","year":"2023","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2337\/dsi25-0001","article-title":"Connected insulin pens and pen caps: expanding diabetes technology access and adoption","volume":"38","author":"MacLeod","year":"2025","journal-title":"Diabetes Spectr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0365","article-title":"Shining the spotlight on multiple daily insulin therapy: real-world evidence of the inpen smart insulin pen","volume":"26","author":"MacLeod","year":"2024","journal-title":"Diabetes Technol. Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2019.0411","article-title":"Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen","volume":"22","author":"Adolfsson","year":"2020","journal-title":"Diabetes Technol. Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","article-title":"Continuous glucose monitoring and metrics for clinical trials: an international consensus statement","volume":"11","author":"Battelino","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/ds18-0100","article-title":"Automated insulin delivery algorithms","volume":"32","author":"Cinar","year":"2019","journal-title":"Diabetes Spectr"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.2337\/dc23-Srev","article-title":"Summary of revisions: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15217","article-title":"Twelve-month results of the adapt randomized controlled trial: reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes","volume":"25","author":"Edd","year":"2023","journal-title":"Diabetes Obes. Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2023.0319","article-title":"12-month efficacy of advanced hybrid closed-loop system in adult type 1 diabetes patients","volume":"26","author":"Nigi","year":"2024","journal-title":"Diabetes Technol. Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-024-00013-5","article-title":"Type 1 diabetes: from the dream of automated insulin delivery to a fully artificial pancreas","volume":"30","author":"Phillip","year":"2024","journal-title":"Nat. Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11648","article-title":"An overview of advancements in closed-loop artificial pancreas system","volume":"8","author":"Dermawan","year":"2022","journal-title":"Heliyon"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00823-z","article-title":"The do-it-yourself artificial pancreas: a comprehensive review","volume":"11","author":"Kesavadev","year":"2020","journal-title":"Diabetes Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1038\/s41467-024-50764-5","article-title":"Personalized insulin dosing using reinforcement learning for high-fat meals and aerobic exercises in type 1 diabetes: a proof-of-concept trial","volume":"15","author":"Jafar","year":"2024","journal-title":"Nat. Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2506549","article-title":"Stem cell-derived, fully differentiated islets for type 1 diabetes","volume":"393","author":"Reichman","year":"2025","journal-title":"N Engl. J. Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02055-5","article-title":"Encapsulated Stem cell-derived beta Cells exert glucose control patients type 1 diabetes","volume":"42","author":"Keymeulen","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.09.004","article-title":"Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.stem.2024.12.005","article-title":"Pluripotent stem-cell-derived therapies in clinical trial: a 2025 update","volume":"32","author":"Kirkeby","year":"2025","journal-title":"Cell Stem Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0033","article-title":"Teplizumab: the first treatment to delay the progression of type 1 diabetes","volume":"41","author":"Goldman","year":"2023","journal-title":"Clin. Diabetes"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-cd3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl. J. Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308743","article-title":"Teplizumab and beta-cell function in newly diagnosed type 1 diabetes","volume":"389","author":"Ramos","year":"2023","journal-title":"N Engl. J. Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0573","article-title":"Oral insulin delay of stage 3 type 1 diabetes revisited in hla dr4-dq8 participants in the trialnet oral insulin prevention trial (tn07)","volume":"47","author":"Zhao","year":"2024","journal-title":"Diabetes Care"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.02.001","article-title":"Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate","volume":"31","author":"Hu","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503822","article-title":"Survival of transplanted allogeneic beta cells with no immunosuppression","volume":"393","author":"Carlsson","year":"2025","journal-title":"N Engl. J. Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13098-023-00983-5","article-title":"Novel targets for potential therapeutic use in diabetes mellitus","volume":"15","author":"Dhankhar","year":"2023","journal-title":"Diabetol. Metab. Syndr"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1440456","article-title":"A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents","volume":"15","author":"Tegegne","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3390\/biom9030106","article-title":"Plant-derived bioactives in oral mucosal lesions: a key emphasis to curcumin, lycopene, chamomile, aloe vera, green tea and coffee properties","volume":"9","author":"Salehi","year":"2019","journal-title":"Biomolecules"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110688","article-title":"Curcumin nanoparticles have potential antioxidant effect and restore tetrahydrobiopterin levels in experimental diabetes","volume":"131","author":"Abu-Taweel","year":"2020","journal-title":"BioMed. Pharmacother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/636053","article-title":"Curcumin and diabetes: a systematic review","volume":"2013","author":"Zhang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3390\/nu11081837","article-title":"Curcumin and type 2 diabetes mellitus: prevention and treatment","volume":"11","author":"Pivari","year":"2019","journal-title":"Nutrients"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2018.09.010","article-title":"In-vivo anti-diabetic and wound healing potential of chitosan\/alginate\/maltodextrin\/pluronic-based mixed polymeric micelles: curcumin therapeutic potential","volume":"120","author":"Akbar","year":"2018","journal-title":"Int. J. Biol. Macromol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1375892","article-title":"Therapeutic applications of curcumin in diabetes: a review and perspective","volume":"2022","author":"Quispe","year":"2022","journal-title":"BioMed. Res. Int"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/molecules25061397","article-title":"Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review","volume":"25","author":"Stohs","year":"2020","journal-title":"Molecules"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e3655","DOI":"10.1002\/dmrr.3655","article-title":"Probiotics, prebiotics, and synbiotics in type 1 diabetes mellitus: a systematic review and meta-analysis of clinical trials","volume":"40","author":"Moravejolahkami","year":"2024","journal-title":"Diabetes Metab. Res. Rev"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00125","article-title":"Evaluating the causal role of gut microbiota in type 1 diabetes and its possible pathogenic mechanisms","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01345","article-title":"Clostridium butyricum cgmcc0313.1 protects against autoimmune diabetes by modulating intestinal immune homeostasis and inducing pancreatic regulatory t cells","volume":"8","author":"Jia","year":"2017","journal-title":"Front. Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113429","article-title":"Paeoniflorin protects nod mice from t1d through regulating gut microbiota and tlr4 mediated myd88\/trif pathway","volume":"422","author":"Luo","year":"2023","journal-title":"Exp. Cell Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1038\/s41598-022-07203-6","article-title":"Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study","volume":"12","author":"Cabrera","year":"2022","journal-title":"Sci. Rep"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2015.2757","article-title":"Association of early exposure of probiotics and islet autoimmunity in the teddy study","volume":"170","author":"Uusitalo","year":"2016","journal-title":"JAMA Pediatr"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/healthcare12151485","article-title":"Exploring novel treatment modalities for type 1 diabetes mellitus: potential and prospects","volume":"12","author":"Salama","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s43856-024-00478-y","article-title":"Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review","volume":"4","author":"Felton","year":"2024","journal-title":"Commun. Med. (Lond)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1551467","article-title":"Epidemiological trends and risk factors of ckd-t1dm in children and adolescents across 204 countries and territories (1990-2021)","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1654","article-title":"Immunotherapy: building a bridge to a cure for type 1 diabetes","volume":"373","author":"Bluestone","year":"2021","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.abh1657","article-title":"Strategies for durable beta cell replacement in type 1 diabetes","volume":"373","author":"Brusko","year":"2021","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the dcct\/edic study 30-year follow-up","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"B65","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc24-SINT","article-title":"Introduction and methodology: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the american diabetes association (ada) and the european association for the study of diabetes (easd)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1177\/1932296820983863","article-title":"Digital diabetes management: a literature review of smart insulin pens","volume":"16","author":"Heinemann","year":"2022","journal-title":"J. Diabetes Sci. Technol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2021.106370","article-title":"Digital interventions self-management education for type 1 and 2 diabetes: a systematic review and meta-analysis","volume":"210","author":"Nkhoma","year":"2021","journal-title":"Comput. Methods Programs BioMed"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1651061\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:29:09Z","timestamp":1760074149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2025.1651061\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":68,"alternative-id":["10.3389\/fcdhc.2025.1651061"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2025.1651061","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"article-number":"1651061"}}